Regeneron Pharmaceuticals ((REGN)), Sanofi SA ((SNY)), Sanofi ((DE:SNW)), Sanofi ((SNYNF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Regeneron Pharmaceuticals and Sanofi are conducting a study titled ‘A U.S. Registry of Eosinophilic Esophagitis Patients Treated With DUPIXENT® As Standard of Care.’ The study aims to understand the use of DUPIXENT® (dupilumab) in treating eosinophilic esophagitis (EoE) and its impact on patients’ quality of life and symptoms. This research is significant as it could inform future treatment decisions and clinical trial designs for EoE.
The intervention being tested is the drug dupilumab, marketed as DUPIXENT®. It is used as a standard treatment for EoE, with the study observing its use in regular clinical practice rather than providing it as an investigational agent.
This observational study follows a cohort model with a prospective time perspective. It is designed as a patient registry over a target duration of three years, focusing on gathering data through patient questionnaires about their experiences and symptoms.
The study began on November 22, 2024, with its primary completion and estimated completion dates yet to be announced. The latest update was submitted on August 6, 2025, indicating ongoing recruitment and data collection.
This study update could positively influence the stock performance of Regeneron and Sanofi by reinforcing investor confidence in DUPIXENT®’s market potential for EoE treatment. As the study progresses, it may also impact the competitive landscape in the pharmaceutical industry, particularly among companies developing treatments for EoE.
The study is currently ongoing, with further details available on the ClinicalTrials portal.